DOCSLIB.ORG

US 2009/0061024 A1 Eppler Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US 2009/0061024 A1 Eppler Et Al US 2009006 1024A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0061024 A1 Eppler et al. (43) Pub. Date: Mar. 5, 2009 (54) COMPOSITIONS AND METHODS (22) Filed: Aug. 26, 2008 EMPLOYING NMDA ANTAGONSTS FOR ACHIEVING AN ANESTHETC-SPARING Related U.S. Application Data EFFECT (60) Provisional application No. 60/968,236, filed on Aug. 27, 2007. (75) Inventors: Cecil Mark Eppler, Langhome, PA (US); David Robert Hustead, Publication Classification Overland Park, KS (US); Thomas (51) Int. Cl. Gerard Cullen, Milltown, NJ (US); A633/00 (2006.01) Raphael Johannes Zwijnenberg, A63/675 (2006.01) Lambertville, NJ (US); William W. A6IP 23/00 (2006.01) Muir, III, Columbus, OH (US) (52) U.S. Cl. ........................................... 424/718; 514/79 Correspondence Address: (57) ABSTRACT WYETH PATENT LAW GROUP Provided herein are compositions, combinations, and meth 5 GRALDA FARMS ods comprising NMDA antagonists including, but not limited MADISON, NJ 07940 (US) to, NMDA glutamate receptor antagonists such as 2-(8.9- dioxo-2,6-diazabicyclo5.2.0non-1-(7)-en-2-yl)alkylphos (73) Assignee: Wyeth, Madison, NJ (US) phonic acid and derivatives thereof, which are effective in reducing the amount of anesthetic required to maintain anes (21) Appl. No.: 12/198,489 thesia (i.e. to achieve an anesthetic-sparing effect). US 2009/006 1024 A1 Mar. 5, 2009 COMPOSITIONS AND METHODS 14:46-50 (1991)), reaching the approximately 50% level only EMPLOYING NMDA ANTAGONSTS FOR at distinctly non-clinical doses (Hall et al., Anesthesiology ACHIEVING AN ANESTHETC-SPARING 68:862-866 (1988)) where side effects such as respiratory EFFECT depression and reduced analgesic efficacy of concurrently used opioids may occur (Gear et al., Pain 71:25-29 (1997) and CROSS-REFERENCE TO RELATED Daghero et al., Anesthesiology 66:944-947 (1987)). APPLICATIONS 0007 Glutamate and aspartate play dual roles in the cen tral nervous system (CNS) as essential amino acids and as the 0001. This application claims the benefit under 35 U.S.C. principal excitatory neurotransmitters. There are at least four S119(e) to U.S. provisional application no. 60/968,236, filed classes of excitatory amino acid receptors: NMDA (N-me Aug. 27, 2007, each of which is hereby incorporated by thyl-D-aspartate), AMPA (2-amino-3-(methyl-3-hydroxy reference in its entirety. isoxazol-4-yl)propanoic acid), kainate, and metabotropic receptors. These excitatory amino acid receptors regulate a BACKGROUND OF THE DISCLOSURE wide range of signaling events that impact physiological 0002 1. Technical Field of the Disclosure brain functions. For example, activation of the NMDA recep 0003. The present disclosure relates generally to the field tor has been shown to be the central event that leads to exci of medicine, including veterinary medicine. More specifi totoxicity and neuronal death in many disease states, as well cally, the present disclosure provides compositions, combi as a result of hypoxia and ischemia following head trauma, nations, kits and methods comprising NMDA glutamate stroke, and following cardiac arrest. It is also known that the receptor antagonists including, but not limited to, the com NMDA receptor plays a major role in the synaptic plasticity pound: 2-(8,9-dioxo-2,6-diazabicyclo5.2.0 non-1-(7)-en that underlies many higher cognitive functions, such as 2-yl)ethylphosphonic acid and derivatives thereof, which memory and learning, certain nociceptive pathways, and in compounds, compositions, combinations kits and methods the perception of pain. In addition, certain properties of are effective for achieving an anesthetic-sparing effect. NMDA receptors suggest that they may be involved in the 0004 2. Description of the Related Art information-processing in the brain that underlies conscious 0005 Anesthetic-sparing effects have been noted for sev ness itself (above information. (Reviewed in Petrenko et al., eral classes of drugs used to complement the beneficial Anesth. Analg.97:1108-1116 (2003)). effects, and/or mitigate undesirable side effects, of anesthet 0008 NMDA glutamate receptors (or “NMDA recep ics. These so-called “anesthetic adjuvant” drugs include C-2 tors') are localized throughout the CNS and in nerves pro adrenergic agonists (Soares et al., American Journal of Vet jecting from the CNS to peripheral tissues. NMDA receptors erinary Research 96:854-859 (2004) and Muir and Lerch, are ligand-gated cation channels that modulate Sodium, Am. J. Vet. Res.67:782-789 (2006)), benzodiazepines (Hallet potassium, and calcium ion flux when they are activated by al., Anesthesiology 68:862-866 (1988)); and opioids glutamate in combination with glycine (reviewed by Childers (Machado et al., Veterinary Anesthesia and Analgesia 33:70 and Baudy, Journal of Medicinal Chemistry 50:2557-2562 77 (2006) and Muir et al., Am. J. Vet. Res. 64:1-6 (2003)). (2007)). Functional NMDA receptors are heterotetramers, Anesthetic sparing can also be achieved by blocking NMDA consisting of 1-3 NR1 subunits and 1-3 NR2 subunits (gen glutamate receptors. Ketamine, a non-competitive NMDA erally depicted as 2 NR1+2 NR2). This heterogeneity is glutamate receptor antagonist, is commonly used as a hyp greatly augmented by the existence of at least 8 NR1 splice notic/dissociative/analgesic adjuvant for anesthetics. The variants and 4 NR2 subunits (NR2A-NR2D). NR1 subunits, anesthetic-sparing effects of 10-20% provided by ketamine at which can constitute ion channels when expressed alone, doses typically used clinically are rather modest (Muir et al., contain the glycine-binding site. NR2 subunits, which are Am. J. Vet. Res. 64:1-6 (2003)), but are still considered one of necessary for full ion conductance, contain the glutamate the benefits of ketamine as an anesthetic adjuvant. binding site and also allosteric modulatory sites for 0006. The anesthetic-sparing effects attainable through polyamines and Zn". The NMDA receptor also contains a currently used anesthetic adjuvant drugs are limited by unde Mg" binding site located inside the pore of the ion channel, sirable side effects, however. For example, the dissociative which blocks ion flow through the channel when occupied by and other dysphoric effects of ketamine referenced above can Mg". persist into the post-Surgical setting, where they are consid 0009 Activation of NMDA receptors plays a major role in ered undesirable side-effects. Ketamine is often administered the induction of pain associated with peripheral tissue and by IV infusion at relatively low doses rather than by a bolus nerve injury (Sindrup et al., Pain 83:389-400 (1999) and IV injection (which would be more convenient) to avoid these Salter, Cur. Topics in Med. Chem. 5:557-567 (2005)). Under side effects. Use-limiting side effects of otheranesthetic adju conditions of normal (nociceptive) pain, the excitatory signal vant drugs include bradycardia for both C-2 adrenergicago received from afferent neurons in the spinal cord dorsal horn nists (Salmenperra et al., Anesthesiology 80:837-846 (1994)) is mediated primarily by the fast-inactivating kainate and and opioids (Ilkiw et al., Canadian Journal of Veterinary AMPA subtypes of the glutamate receptor. Painful stimuli of Research 58:248-253 (1994)) and respiratory depression for greater duration and intensity result in accumulating, pro opioids (van den Berget al., British Journal of Clinical Phar longed, slowly depolarizing synaptic potentials that relieve macology38:533-543 (1994); Willette et al., Journal of Phar the NMDA subtype of the glutamate receptor from its tonic macology and Experimental Therapeutics 240:352-358 block by Mg" ions. Activation of NMDA receptors accentu (1987)). Although benzodiazepines can provide significant ates the Sustained depolarization and contributes to an anesthetic-sparing effects, they tend to be rather modest (typi increase in the discharge of dorsal horn nociceptive neurons cally less than 25%) at doses used clinically (Tranquilliet al., in a process called “wind-up.” Prolonged activation of American J. of Vet. Res. 52:662-664 (1991); Muir et al., NMDA receptors can lead to modifications in cellular signal Journal of Veterinary Pharmacology and Therapeutics ing pathways that enhance the responsiveness of the nocice US 2009/006 1024 A1 Mar. 5, 2009 ptive neuron to activation in a collection of processes referred 48: 1212-1218 (1997) and Sang et al... Anesthesiology to as “central sensitization.” The elements of central sensiti 96:1053-1061 (2002)) and, with mixed success, for postop Zation, Such as reversible post-translational modification of erative pain as an adjunct to opioids (Duedahl et al., Acta proteins, may act over both the short term and longer term. Anesthesiol. Scand. 50: 1-13 (2006)). Amantadine has been Central sensitization includes both short-term, reversible used to treat postSurgical neuropathic pain in cancer patients components (such as post-translational modification of pro (Pud et al., Pain 75:349-354 (1998)) and phantom limb pain teins) and long-term elements. One Such long-term element (Wiech et al., Anesth. Analg. 98:408-413 (2004)). thought to be associated with neuropathic pain is an enhanced 0013 Clinical usefulness of the noncompetitive channel response of the NMDA receptor itself to excitatory input blocking NMDA antagonists has, however, been limited by through up-regulation of the modulatory tyrosine kinase Src. adverse effects Such as auditory and visual disturbances and Yu and Salter, Proc. Natl. Acad. Sci. U.S.A. 96:7697-7704 hallucinations, feelings of unreality, feelings of detachment (1999). from the body, dizziness, sedation, nausea, and Vomiting 0010 Earlier demonstrations that NMDA receptor (Chizh and Hedley, Curr: Pharm. Design 11:2977-2994 antagonists could inhibit the “wind-up' response had pro (2005); Kohrs and Durieux, Anesth. Analg. 87:1186-1193 vided the initial evidence for involvement of NMDA recep (1998); and Max et al., Clin. Neuropharm. 18:360-368 tors in central sensitization and supported further efforts to (1995)). Some of these effects are similar to those of phen develop novel analgesics targeting this mechanism.
Load more

Recommended publications
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • Bond Donors for Selective Anion Recognition
    FULL PAPER Deltamides and croconamides: expanding the range of dual H- bond donors for selective anion recognition Vincent E. Zwicker,[a],‡ Karen K. Y. Yuen,[a],‡ David G. Smith,[a] Junming Ho,[b] Lei Qin,[a] Peter Turner[a] and Katrina A. Jolliffe[a],* Abstract: Dual H-bond donors are widely used as recognition motifs match for Y-shaped anions such as carboxylates.3 Dual hydrogen in anion receptors. We report the synthesis of a library of dual H-bond bond donors have also been shown to have superior hydrogen receptors, incorporating the deltic and croconic acid derivatives, bond donicity to monodentate hydrogen bond donors of similar termed deltamides and croconamides, and a comparison of their acidity,4 providing improved anion binding capacity, together with anion binding affinities (for monovalent species) and Brønsted a decreased propensity for the receptor to be deprotonated by acidities to those of the well-established urea and squaramide dual H- basic anions. This latter property is of particular importance in the bond donor motifs. For dual H-bond cores with identical substituents, development of new anion binding motifs, since if a hydrogen the trend in Brønsted acidity is croconamides > squaramides bond donor is too acidic, it is no longer effective at binding to 5 >deltamides > ureas, with the croconamides found to be 10-15 pKa anions at neutral pH. Finding dual hydrogen bonding motifs with units more acidic than the corresponding ureas. In contrast to the the right balance between hydrogen bond donicity and Brønsted trends displayed by ureas, deltamides and squaramides, N,N’-dialkyl acidity should provide improved anion receptors and allow them croconamides displayed higher binding affinity to chloride than the to be tailored towards specific anions.
    [Show full text]
  • Some Unusual, Astronomically Significant Organic Molecules
    'lL-o Thesis titled: Some Unusual, Astronomically Significant Organic Molecules submitted for the Degree of Doctor of Philosophy (Ph,D.) by Salvatore Peppe B.Sc. (Hons.) of the Department of Ghemistty THE UNIVERSITY OF ADELAIDE AUSTRALIA CRUC E June2002 Preface Gontents Contents Abstract IV Statement of Originality V Acknowledgments vi List of Figures..... ix 1 I. Introduction 1 A. Space: An Imperfect Vacuum 1 B. Stellff Evolution, Mass Outflow and Synthesis of Molecules 5 C. Astronomical Detection of Molecules......... l D. Gas Phase Chemistry.. 9 E. Generation and Detection of Heterocumulenes in the Laboratory 13 L.2 Gas Phase Generation and Characterisation of Ions.....................................16 I. Gas Phase Generation of Ions. I6 A. Positive Ions .. I6 B. Even Electron Negative Ions 17 C. Radical Anions 2t tr. Mass Spectrometry 24 A. The VG ZAB 2}lF Mass Spectrometer 24 B. Mass-Analysed Ion Kinetic Energy Spectrometry......... 25 III. Characterisation of Ions.......... 26 A. CollisionalActivation 26 B. Charge Reversal.... 28 C. Neutralisation - Reionisation . 29 D. Neutral Reactivity. JJ rv. Fragmentation Behaviour ....... 35 A. NegativeIons.......... 35 Preface il B. Charge Inverted Ions 3l 1.3 Theoretical Methods for the Determination of Molecular Geometries and Energetics..... ....o........................................ .....39 L Molecular Orbital Theory........ 39 A. The Schrödinger Equation.... 39 B. Hartree-Fock Theory ..44 C. Electron Correlation ..46 D. Basis sets............ .51 IL Transition State Theory of Unimolecular Reactions ......... ................... 54 2. Covalently Bound Complexes of CO and COz ....... .........................58 L Introduction 58 tr. Results and Discussion........... 59 Part A: Covalently bound COz dimers (OzC-COr)? ............ 59 A. Generation of CzO¿ Anions 6I B. NeutralCzO+........
    [Show full text]
  • Hydrates and Polymorphs of Lead Squarate Pb(C4O4): Structural Transformations Studied by in Situ X-Ray Powder Diffraction and Solid State NMR Thierry Bataille, A
    Hydrates and polymorphs of lead squarate Pb(C4O4): Structural transformations studied by in situ X-ray powder diffraction and solid state NMR Thierry Bataille, A. Bouhali, Cassendre Kouvatas, C. Trifa, Nathalie Audebrand, C. Boudaren To cite this version: Thierry Bataille, A. Bouhali, Cassendre Kouvatas, C. Trifa, Nathalie Audebrand, et al.. Hy- drates and polymorphs of lead squarate Pb(C4O4): Structural transformations studied by in situ X-ray powder diffraction and solid state NMR. Polyhedron, Elsevier, 2019, 164, pp.123-131. 10.1016/j.poly.2019.02.047. hal-02090016 HAL Id: hal-02090016 https://hal-univ-rennes1.archives-ouvertes.fr/hal-02090016 Submitted on 6 Jun 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Hydrates and polymorphs of lead squarate Pb(C4O4): structural transformations studied by in situ X-ray powder diffraction and solid state NMR Thierry Bataille*,a Amira Bouhali,b Cassandre Kouvatas,a,c Chahrazed Trifa,b Nathalie Audebrand,a Chaouki Boudaren b a Univ Rennes, Ecole Nationale Supérieure de Chimie de Rennes, CNRS, ISCR -
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives As Potent Cholinesterase Inhibitors
    biomolecules Article Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors 1,2, 1,2,3, 1,2 1,2 Barbora Svobodova y, Eva Mezeiova y, Vendula Hepnarova , Martina Hrabinova , Lubica Muckova 1,2 , Tereza Kobrlova 1 , Daniel Jun 1,2 , Ondrej Soukup 1,2, María Luisa Jimeno 4, José Marco-Contelles 3,* and Jan Korabecny 1,2,* 1 Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic 2 Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic 3 Laboratory of Medicinal Chemistry, Institute of General Organic Chemistry, Juan de la Cierva 3, 28006-Madrid, Spain 4 Centro de Química Orgánica “Lora-Tamayo” (CSIC), C/Juan de la Cierva 3, 28006-Madrid, Spain * Correspondence: [email protected] (J.M.-C.); [email protected] (J.K.); Tel.: +34-91-2587554 (J.M.-C.); +420-495-833-447 (J.K.) These authors contributed equally to this paper. y Received: 2 August 2019; Accepted: 17 August 2019; Published: 19 August 2019 Abstract: Tacrine was the first drug to be approved for Alzheimer’s disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. The portfolio of currently approved drugs for AD includes acetylcholinesterase inhibitors (AChEIs) and N-methyl-d-aspartate (NMDA) receptor antagonist. Squaric acid is a versatile structural scaffold capable to be easily transformed into amide-bearing compounds that feature both hydrogen bond donor and acceptor groups with the possibility to create multiple interactions with complementary sites.
    [Show full text]
  • Application of Squaric Acid to the Preparation of Bioactive Compounds
    Application of Squaric Acid to The Preparation of Bioactive Compounds By Meijun Lu A thesis presented to the University of Waterloo in fulfillment of the thesis requirement for the degree of Master of Science in Chemistry Waterloo, Ontario, Canada, 2008 © Meijun Lu 2008 I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. ii ABSTRACT Nucleosides and nucleoside analogues exhibit a broad spectrum of biological activities including antiviral, anticancer, antibacterial and antiparasitic activities, which generally result from their ability to inhibit specific enzymes. Nucleoside analogues can interact with cellular enzymes involved in the biosynthesis or degradation of RNA (ribonucleic acid) and/or DNA (deoxyribonucleic acid) or with specific viral enzymes to result in their biological activities and therapeutic effects. In addition, another possible target is their incorporation into DNA/RNA which could affect replication and transcription. They have been beneficial to the development of new pharmaceuticals. Squaric acid and its derivatives have been successfully used as a bioisosteric group in various biomedicinal areas. The aim of this research proposal was to apply squaric acid analogues to the design and synthesis of novel nucleoside analogues. Three squaric acid-based new nucleoside analogues were made starting from dimethyl squarate. The compounds were 4-amino-3-[((1R,3S)-3-hydroxymethyl-4-cyclopentene)- 1-amino]-3-cyclobutene-1,2-dione, 4-methoxy-3-[((1R,3S)-3-hydroxymethyl-4-cyclopen tene)-1-amine]-3-cyclobutene-1,2-dione, and 4-hydroxy-3-[((1R,3S)-3-hydroxymethyl-4- cyclopentene)-1-amine]-3-cyclobutene-1,2-dionate, sodium salt.
    [Show full text]
  • Croconate Salts. New Bond-Delocalized Dianions, &Q
    JOURNAL OF RESEARCH of the National Bureau of Standards Volume 85, No.2, March·April1980 Pseudo-Oxocarbons. Synthesis of 2, 1,3-Bis-, and 1, 2, 3-Tris (Dicyanomethylene) Croconate Salts. New Bond-Delocalized Dianions, "Croconate Violet" and "Croconate Blue"* Alexander J. Fatiadit National Bureau of Standards, Washington, D.C. 20234 October 24,1979 Synthesis and characteri zation of new bond·delocalized dianions, e.g., 2, 1,3·bis·, 1,2, 3·tris (di cyanomethyl. ene) croconate salts have been described. The dianions re ported represent a new class of aromati c, nonbenze· noid co mpounds, named pseudo·oxocarbons. A study of their physical, analytical and chemical properties offer a new direction in the chemistry of oxocarbons. Key words: Acid; aromatic; bond·delocalized; croco nic; diani on; malononitrile; nonbenzenoid; oxocarbon; salt; synthesis 1. Introduction molecular properties of the croconic salts (e.g. 2 , dipotas­ sium salt) were first seriously investigated when a symmetri­ The bright ye ll ow dipotassium croconate 1 and croconic cal, delocalized structure fo r the dianion 2 was proposed by acid (1 , K = H, 4,5-dihydroxy-4--cyclopentene-l,2,3-trione) Yamada et aJ. [3] in 1958. A few years later [4], the d i anion 2 were first isolated by Gmelin [1]' in 1825, from the black, ex· and the related deltate [5], squarate, rhodizonate, and plosive, side-reaction product (e.g. K6 C6 0 6 + KOC=COK), tetrahydroxyquinone anions were recognized by West et aJ. by the reaction of carbon with potassium hydroxide, in a [2,4] as members of a new class of aromatic oxocarbons pioneer, industrial attempt to manufacture potassium.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Discovery and Development of Veterinary Pharmaceuticals in Telemetered Animals
    DISCOVERY AND DEVELOPMENT OF VETERINARY PHARMACEUTICALS IN TELEMETERED ANIMALS R. J. G. Zwijnenberg 2010 ISBN: 978‐90‐39354742 DISCOVERY AND DEVELOPMENT OF VETERINARY PHARMACEUTICALS IN TELEMETERED ANIMALS Ontdekking en ontwikkeling van veterinaire farmaceutische produkten in van telemeters voorziene dieren (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. J.C. Stoof, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 14 december 2010 des middags te 2.30 uur door: Raphaёl Johannes Gerhardus Zwijnenberg geboren op 22 december 1961 te Winterswijk Promotor: Prof. dr. J. Kirpensteijn Colophon My parents own a house in Palma de Gandia, Valencia, Spain. It is a typically Spanish house with many terraces and retaining walls. All these retaining walls have been built by hand by my parents. As they were building the retaining walls in their garden, my parents lovingly named each one of these walls by a different name. E.g. the longest wall was called “la Langedocienne” after a piece of the French autoroute that is long and doesn’t seem to end. The one wall I tried to help construct my parents named the “klaagmuur” in Dutch. The translation in English means “the wall of complaints” as the Wailing Wall is called in Dutch. I must have complained a lot during construction, or at least my parents thought so. Also doing a PhD by publication, as is the custom in the Netherlands, is a long process of writing and re‐ writing articles, sign‐off procedures, satisfying both scientific and company standards and procedures.
    [Show full text]